Table 2.
Cox univariate and multivariate analysis of OS (A) and DFS (B) in patients with breast cancer.
| Risk factors | Univariate analysis | Multivariate analysis | Score | ||
|---|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | ||
| A | |||||
| Cbl-b | |||||
| Positive | 1 | 1 | 0 | ||
| Negative | 1.817 (1.126–2.933) | 0.014 | 1.705 (1.054–2.759) | 0.03 | 1 |
| Age (years) | |||||
| >35 | 1 | 1 | 0 | ||
| ≤ 35 | 4.105 (1.961–8.592) | <0.001 | 3.922 (1.863–8.254) | <0.001 | 2 |
| Tumor size | |||||
| ≤ 2 cm | 1 | 0 | |||
| >2 cm | 2.504 (1.343–4.667) | 0.004 | 1.896 (1.008–3.565) | 0.047 | 1 |
| Lymph node metastasis | |||||
| No | 1 | 1 | 0 | ||
| Yes | 3.371 (1.874–6.064) | <0.001 | 2.874 (1.588–5.202) | <0.001 | 2 |
| Histology grade | |||||
| 1 or unknown | 1 | 1 | 0 | ||
| 2–3 | 2.843 (1.300–6.215) | 0.009 | 2.376 (1.081–5.220) | 0.031 | 1 |
| Stage | |||||
| 0–I | 1 | ||||
| II–III | 5.430 (1.707–17.270) | 0.004 | |||
| HR | |||||
| Negative | 1 | ||||
| Positive | 1.138 (0.702–1.846) | 0.6 | |||
| HER2 | |||||
| Negative | 1 | ||||
| Positive | 1.612 (0.996–2.610) | 0.052 | |||
| Date of diagnosis | |||||
| 2004–2008 | 1 | ||||
| 1999–2003 | 1.307 (0.808–2.114) | 0.276 | |||
| Neoadjuvant chemotherapy | |||||
| No | 1 | ||||
| Yes | 2.147 (0.675–6.834) | 0.196 | |||
| Adjuvant chemotherapy | 0.357 | ||||
| Anthracycline-based only | 1 | ||||
| Taxane-based only | 0.978 (0.134–7.141) | 0.982 | |||
| Anthracycline & taxane-based | 1.309 (0.783–2.189) | 0.304 | |||
| Others | 1.941 (0.900–4.186) | 0.091 | |||
| Endocrine therapy | |||||
| No | 1 | ||||
| Yes | 1.161 (0.715–1.883) | 0.546 | |||
| Radiotherapy | |||||
| No | 1 | ||||
| Yes | 1.937 (1.207–3.109) | 0.006 | |||
| Trastuzumab therapy | |||||
| No | 1 | ||||
| Yes | 2.374 (0.746–7.556) | 0.143 | |||
| Surgery type | 0.841 | ||||
| Radical mastectomy | 1 | ||||
| Breast-conserving surgery | 0 | 0.974 | |||
| Simple mastectomy | 1.806 (0.251–13.012) | 0.557 | |||
| Menstrual status | |||||
| Premenopausal | 1 | ||||
| Postmenopausal | 1.006 (0.626–1.617) | 0.982 | |||
| Age (years) | |||||
| ≤ 50 | 1 | ||||
| >50 | 0.997 (0.621–1.599) | 0.989 | |||
| B | |||||
| Cbl-b | |||||
| Positive | 1 | 1 | 0 | ||
| Negative | 1.623 (1.091–2.416) | 0.017 | 1.612 (1.082–2.402) | 0.019 | 1 |
| Age (years) | |||||
| >35 | 1 | 1 | 0 | ||
| ≤ 35 | 2.517 (1.221–5.188) | 0.012 | 2.980 (1.406–6.315) | 0.004 | 2 |
| Tumor size | |||||
| ≤ 2cm | 1 | ||||
| >2 cm | 1.965 (1.214–3.183) | 0.006 | |||
| Lymph node metastasis | |||||
| No | 1 | 1 | 0 | ||
| Yes | 2.741 (1.730–4.342) | < 0.001 | 2.569 (1.619–4.076) | < 0.001 | 2 |
| Histology grade | |||||
| 1 or unknown | 1 | 1 | 0 | ||
| 2–3 | 2.050 (1.144–3.674) | 0.016 | 1.933 (1.075–3.477) | 0.028 | 1 |
| Stage | |||||
| 0–I | 1 | ||||
| II–III | 3.915 (1.714–8.941) | 0.001 | |||
| HR | |||||
| Negative | 1 | ||||
| Positive | 1.131 (0.756–1.693) | 0.55 | |||
| HER2 | |||||
| Negative | 1 | ||||
| Positive | 1.251 (0.832–1.881) | 0.281 | |||
| Date of diagnosis | |||||
| 2004–2008 | 1 | 1 | 0 | ||
| 1999–2003 | 1.691 (1.137–2.514) | 0.009 | 1.905 (1.262–2.876) | 0.002 | 1 |
| Neoadjuvant chemotherapy | |||||
| No | 1 | ||||
| Yes | 1.310 (0.415–4.134) | 0.645 | |||
| Adjuvant chemotherapy | 0.562 | ||||
| Anthracycline-based | 1 | ||||
| Taxane-based | 0.563 (0.078–4.072) | 0.569 | |||
| Anthracycline & taxane-based | 1.303 (0.858–1.981) | 0.215 | |||
| Others | 1.198 (0.569–2.523) | 0.634 | |||
| Endocrine therapy | |||||
| No | 1 | ||||
| Yes | 1.154 (0.771–1.728) | 0.486 | |||
| Radiotherapy | |||||
| No | 1 | ||||
| Yes | 1.801 (1.209–2.683) | 0.004 | |||
| Trastuzumab therapy | |||||
| No | 1 | ||||
| Yes | 2.079 (0.764–5.653) | 0.152 | |||
| Surgery type | 0.839 | ||||
| Radical mastectomy | 1 | ||||
| Breast–conserving surgery | 0 | 0.968 | |||
| Simple mastectomy | 1.812 (0.253–13.005) | 0.554 | |||
| Menstrual status | |||||
| Premenopausal | 1 | ||||
| Postmenopausal | 1.035 (0.697–1.538) | 0.864 | |||
| Age (years) | |||||
| ≤ 50 | 1 | ||||
| >50 | 1.014 (0.683–1.504) | 0.946 | |||
P value shown in bold are statistically significant (two-sided, p < 0.2 in univariate analysis and p < 0.05 in multivariate analysis).
The score of each prognostic factor was calculated based on the ratio of their HR values (the score of the least HR value was set as 1).